RNA epigenetics Target oncology opportunities with EPICS’s focus on small molecule drugs that modulate RNA epigenetic mechanisms, aligning with high-value cancer indications and potential partnerships to accelerate lead optimization and clinical progression.

Series A momentum Capitalize on recent €12M Series A funding and $13.1M financing to engage around partnerships or non-dilutive collaboration opportunities, offering access to EPICS’s emerging oncology pipeline and resources for joint development.

Leadership transition Leverage the appointment of Graeme Fraser as CEO to initiate executive-level outreach, proposing strategic collaborations, licensing, or co-development deals that align with the new leadership’s growth trajectory and messaging.

Early-stage potential Position EPICS as a partner for early-stage discovery and preclinical programs, given their small molecule focus and RNA epigenetic mechanism, offering contract research, target validation, or platform collaboration opportunities.

Strategic partnerships Highlight past collaboration with Ogeda and ongoing oncology focus to approach similar biotechs and pharma companies seeking RNA-targeted oncology solutions, proposing in-licensing or co-development arrangements to expand the pipeline.